472.25

-0.95%↓

SANES

10.206

-1.41%↓

SAF

270.3

-3.57%↓

BBVA

18.525

-1.02%↓

BNP

88.96

-1.65%↓

472.25

-0.95%↓

SANES

10.206

-1.41%↓

SAF

270.3

-3.57%↓

BBVA

18.525

-1.02%↓

BNP

88.96

-1.65%↓

472.25

-0.95%↓

SANES

10.206

-1.41%↓

SAF

270.3

-3.57%↓

BBVA

18.525

-1.02%↓

BNP

88.96

-1.65%↓

472.25

-0.95%↓

SANES

10.206

-1.41%↓

SAF

270.3

-3.57%↓

BBVA

18.525

-1.02%↓

BNP

88.96

-1.65%↓

472.25

-0.95%↓

SANES

10.206

-1.41%↓

SAF

270.3

-3.57%↓

BBVA

18.525

-1.02%↓

BNP

88.96

-1.65%↓

Kodu・Aktsiate loetelu・DBV Technologies SA

D
DBV Technologies SA

Suletud

3.378 0.72

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.358

Max

3.378

Põhinäitajad
By Trading Economics
Sissetulek	-12M -45M
Müük	3.4M 3.4M
Kasumimarginaal	-1,323.179
Töötajad	117
EBITDA	-10M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-2.4% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	595M 1B
Eelmine avamishind	2.66
Eelmine sulgemishind	3.378

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

1.61 / 1.72 Toetus ja vastupanu

DBV Technologies SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. apr 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. apr 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. apr 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. apr 2026, 17:09 UTC

Market Talk

Tulu

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. apr 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 17:06 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. apr 2026, 16:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

24. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

DBV Technologies SA Prognoos

Hinnasiht

By TipRanks

-2.4% langus

12 kuu keskmine prognoos

Keskmine 3.26 EUR -2.4%

Kõrge 5.5 EUR

Madal 1.01 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi DBV Technologies SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi DBV Technologies SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.61 / 1.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.